Avandia Revisited: Will New Findings Lead To Reevaluation of Drug Center's Structure?
This article was originally published in RPM Report
Executive Summary
Senate Finance Committee report and internal FDA analysis on cardiovascular risks associated with GSK's Avandia may revive argument to split CDER into two groups of safety and efficacy reviewers.